Menu Item

Where is the Next Opportunity in Health Care Real Estate?

In an article for RE-NJ, Jay Biggins of BLS & Co. provided his insights on identifying emerging opportunities within the healthcare real estate sector, emphasizing the importance of strategic site selection and the benefits of leveraging state and local incentives.

Here’s what Jay Biggins had to say:

Jay C. Biggins, executive managing director, Biggins Lacy Shapiro & Co. LLC (Princeton)

New Jersey is finally leveraging its “legacy” pharma asset base. Recent successes include diverse new investments, such as large-scale biologics (BeiGene), cell and gene therapies (Cellares) and CDMOs or contract development and manufacturing organizations (Enzyne), with others in the pipeline. Princeton West, the repurposed former Bristol Myers Squibb campus in Hopewell, also is a reminder that you have to invest in ready-to-go sites with power, water and sewer infrastructure to compete for life sciences production opportunities. Ultimately, New Jersey’s life sciences future depends on patient long-term investment — such as the EDA’s investment in HELIX in New Brunswick, AI in Princeton and Edge Works at Liberty Science Center. The mission-critical last ingredient in New Jersey’s life sciences comeback strategy is workforce development.

Jay Biggins

Executive Managing Director

Jay is the Executive Managing Director at Biggins Lacy Shapiro & Co., one of the most highly regarded site selection and incentives advisory firms in North America. BLS & Co. helps manage the complexities associated with finding optimal locations and securing incentives to support new ventures.

Source:
Real Estate New Jersey
right pointing arrow
right pointing arrow
right pointing arrow

the latest from bls & Co.

right pointing arrow

Interested in Learning More?

Contact us today at 609.924.9775 or info@blsstrategies.comto schedule an initial consultation.
Menu Item